Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377089 | 0.94 | CTSS (0.44) | CTSSCTSBPPP3CBCYP3A4ADRB3 | |
| SCHEMBL13337171 | 0.92 | CTSS (0.46) | CTSSCTSBPPP3CBCYP3A4ADRB3 | |
| SCHEMBL1688359 | 0.91 | CTSB (0.45) | CTSSCTSBPPP3CBCYP3A4 | |
| SCHEMBL1688358 | 0.88 | CTSS (0.45) | CTSSCTSBPPP3CBCYP3A4ADRB3 | |
| SCHEMBL16329517 | 0.88 | CTSS (0.45) | CTSSCTSBPPP3CBCYP3A4ADRB3 | |
| SCHEMBL12794498 | 0.87 | CTSB (0.43) | CTSSCTSBPPP3CBCYP3A4 | |
| SCHEMBL7876843 | 0.86 | CTSB (0.43) | CTSSCTSBPPP3CBCYP3A4 | |
| SCHEMBL3478903 | 0.86 | CTSS (0.41) | CTSSCTSBPPP3CBCYP3A4 | |
| SCHEMBL7942657 | 0.85 | CTSB (0.47) | CTSSCTSBPPP3CBCYP3A4 | |
| SCHEMBL3478955 | 0.85 | CTSS (0.42) | CTSSCTSBPPP3CBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CTSS 565/4885CTSB 260/4885PPP3CB 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.